Page 95 - 2019_08-Haematologica-web

Very young patients with ET and PV
sickle cell disease.77 In contrast, the use of interferons was quite uncommon even though these drugs are non-leuke- mogenic and the first line of cytoreductive drugs accord- ing to the European LeukemiaNet recommendations. It is important to remember that all these medications, even hydroxycarbamide, are currently unlicensed in this popu- lation. Also, there are few data concerning the side effects and the long-term consequences of the use of these drugs.
The European LeukemiaNet recommendations do not appear to have been followed closely in the population we analyzed, but at the same time, there are no adapted rec- ommendations for the treatment of MPN in very young patients. This is potentially a substantial shortcoming
since young people are not small adults and also because there is no real large cohort of patients in whom to assess the risks, outcomes and medications in a prospective man- ner. Thus, we propose a large pan-European study con- cerning very young patients. The aims of this study should be multiple: to gain a more accurate overview of the clinical and biological parameters concerning this pop- ulation at diagnosis (symptoms and the way of making the diagnosis) and to obtain a clearer understanding of the incidence of thromboses, hemorrhages and disease pro- gression. Such a study should also federate clinicians and biologists interested in the field in order to manage these patients better with the help of pediatricians.
References
1. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and manage- ment. Am J Hematol. 2017;92(1): 94-108.
2. Barbui T, Barosi G, Birgegard G, et al; European LeukemiaNet. Philadelphia-nega- tive classical myeloproliferative neoplasms: critical concepts and management recom- mendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761-770.
3. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neo- plasms and acute leukemia. Blood. 2016;127(20):2391-2405.
4. Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombo- cythemia, polycythemia vera, and myelofi- brosis. Blood. 2014;124(16):2507-2513.
5. Boddu P, Masarova L, Verstovsek S, et al. Patient characteristics and outcomes in ado- lescents and young adults with classical Philadelphia chromosome-negative myelo- proliferative neoplasms. Ann Hematol. 2018;97(1):109-121.
6. Palandri F, Latagliata R, Polverelli N, et al. Mutations and long-term outcome of 217 young patients with essential thrombo- cythemia or early primary myelofibrosis. Leukemia. 2015;29(6):1344-1349.
7. BarbuiT,ThieleJ,CarobbioA,etal.Disease characteristics and clinical outcome in young adults with essential thrombocythemia ver- sus early/prefibrotic primary myelofibrosis. Blood. 2012;120(3):569-571.
8. Passamonti F, Malabarba L, Orlandi E, et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis,
myelofibrosis and leukemia. Haematologica. 2003;88(1):13-18.
9. Cario H, McMullin MF, Pahl HL. Clinical and hematological presentation of children and adolescents with polycythemia vera. Ann Hematol. 2009;88(8):713-719.
10. Costa G, Petit A, Ianotto JC, et al. Thrombocytémie essentielle (TE) chez l’en- fant et le jeune adulte. Rev Oncol Hematol Ped. 2016;4(4):253-254.
11. El-Moneim AA, Kratz CP, Böll S, Rister M, Pahl HL, Niemeyer CM. Essential versus reactive thrombocythemia in children: retro- spective analyses of 12 cases. Pediatr Blood Cancer. 2007;49(1):52-55.
12. FuR,LiuD,CaoZ,etal.Distinctmolecular
abnormalities underlie unique clinical fea- tures of essential thrombocythemia in chil- dren. Leukemia. 2016;30(3):746-749.
13. Giona F, Teofili L, Moleti ML, et al. Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome. Blood. 2012;119(10): 2219-2227.
14. Giona F, Teofili L, Capodimonti S, et al. CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence. Blood. 2014;123(23):3677- 3679.
15. Ismael O, Shimada A, Hama A, et al. Mutations profile of polycythemia vera and essential thrombocythemia among Japanese children. Pediatr Blood Cancer. 2012;59(3): 530-535.
16. Karow A, Nienhold R, Lundberg P, et al. Mutational profile of childhood myeloprolif- erative neoplasms. Leukemia. 2015;29(12): 2407-2409.
ative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia. Blood. 2007;110(9):3384- 3386.
25. Veselovska J, Pospisilova D, Pekova S, et al. Most pediatric patients with essential thrombocythemia show hypersensitivity to erythropoietin in vitro, with rare JAK2 V617F-positive erythroid colonies. Leuk Res. 2008;32(3):369-377.
26. Aladily TN, Mohammad RS, Al-Khader A, Awidi AS. Essential thrombocythemia in a two-year-old child, responsive to hydroxy- urea but not aspirin. Oman Med J. 2017;32(3):243-246.
27. Beatrice JM, Garanito MP. Essential throm- bocythemia: a rare disease in childhood. Rev Bras Hematol Hemoter. 2013;35(4):287-289.
28. Dua V, Yadav SP, Kumar V, Saxena R, Sachdeva A. Two cases of pediatric essential thrombocythemia managed effectively with hydroxyurea. Int J Hematol. 2012;96(6):810-
17. Langabeer SE, Haslam K, McMahon C. 813.
CALR mutations are rare in childhood essential thrombocythemia. Pediatr Blood Cancer. 2014;61(8):1523.
18. Nakatani T, Imamura T, Ishida H, et al. Frequency and clinical features of the JAK2 V617F mutation in pediatric patients with sporadic essential thrombocythemia. Pediatr Blood Cancer. 2008;51(6):802-805.
19. Putti MC, Pizzi M, Bertozzi I, et al. Bone marrow histology for the diagnosis of essen- tial thrombocythemia in children: a multi- center Italian study. Blood. 2017;129(22): 3040-3042.
20. Randi ML, Geranio G, Bertozzi I, et al. Are all cases of paediatric essential thrombo- cythemia really myeloproliferative neo- plasms? Analysis of a large cohort. Br J Haematol. 2015;169(4):584-589.
21. Randi ML, Putti MC, Scapin M, et al. Pediatric patients with essential thrombo- cythemia are mostly polyclonal and V617FJAK2 negative. Blood. 2006;108(10): 3600-3602.
22. Sekiya Y, Okuno Y, Muramatsu H, et al. JAK2, MPL, and CALR mutations in children with essential thrombocythemia. Int J Hematol. 2016;104(2):266-267.
23. Teofili L, Cenci T, Martini M, et al. The mutant JAK2 allele burden in children with essential thrombocythemia. Br J Haematol. 2009;145(3):430-432.
24. Teofili L, Giona F, Martini M, et al. The revised WHO diagnostic criteria for Ph-neg-
29. Hermeziu B, Franchi-Abella S, Plessier A, et al. Budd-Chiari syndrome and essential thrombocythemia in a child: favorable out- come after transjugular intrahepatic por- tosystemic shunt. J Pediatr Gastroenterol Nutr. 2008;46(3):334-337.
30. Hwang J, Lee W. A case of essential throm- bocythemia in an 8-year-old boy. Pediatr Hematol Oncol. 2008;25(4):325-330.
31. Jaime-Perez JC, Gomez-Almaguer D. Platelet refractoriness to classical agonists in a child with essential thrombocythemia. Platelets. 2005;16(1):61-62.
32. Jensen AW, Tefferi A, Arndt CA. Cerebral venous sinus thrombosis associated with essential thrombocytosis in a pediatric patient. J Pediatr Hematol Oncol. 2007;29(3):156-159.
33. Kanai A, Morokawa H, Matsuda K, Shimazaki E, Nakazawa Y. Efficacy and safety of anagrelide in childhood essential thrombocythemia. Pediatr Int. 2017;59(9): 1017-1018.
34. Khan AA, Kumar V, Anand I, Kumar M, Sharma P, Bhargava M. JAK2 mutation-neg- ative essential thrombocythemia in a child presenting with cerebral venous thrombosis. Hematol Oncol Stem Cell Ther. 2012;5(1): 66-68.
35. Kurosawa H, Okuya M, Matsushita T, et al. JAK2V617F mutation-positive childhood essential thrombocythemia associated with cerebral venous sinus thrombosis. J Pediatr
haematologica | 2019; 104(8)
1587